Sarcoidosis: social predictors of severity at presentation
- PMID: 15459139
- DOI: 10.1183/09031936.04.00070503
Sarcoidosis: social predictors of severity at presentation
Abstract
To determine relationships among social predictors and sarcoidosis severity at presentation, demographic characteristics, socioeconomic status, and barriers to care, A Case-Control Etiologic Study of Sarcoidosis (ACCESS) was set up. Patients self-reported themselves to be Black or White and were tissue-confirmed incident cases aged > or =l8-yrs-old (n=696) who had received uniform assessment procedures within one of 10 medical centres and were studied using standardised questionnaires and physical, radiographical, and pulmonary function tests. Severity was measured by objective disease indicators, subjective measures of dyspnoea and short form-36 subindices. The results of the study showed that lower income, the absence of private or Medicare health insurance, and other barriers to care were associated with sarcoidosis severity at presentation, as were race, sex, and age. Blacks were more likely to have severe disease by objective measures, while women were more likely than males to report subjective measures of severity. Older individuals were more likely to have severe disease by both measures. In conclusion, it was found that low income and other financial barriers to care are significantly associated with sarcoidosis severity at presentation even after adjusting for demographic characteristics of race, sex, and age.
Similar articles
-
Sarcoidosis severity and socioeconomic status.Eur Respir J. 2001 Sep;18(3):499-506. doi: 10.1183/09031936.01.00056201. Eur Respir J. 2001. PMID: 11589347
-
Children's access to primary care: differences by race, income, and insurance status.Pediatrics. 1996 Jan;97(1):26-32. Pediatrics. 1996. PMID: 8545220
-
Race and end-stage renal disease. Socioeconomic status and access to health care as mediating factors.Arch Intern Med. 1995 Jun 12;155(11):1201-8. Arch Intern Med. 1995. PMID: 7763126
-
Sarcoidosis.Med Clin North Am. 2005 Jul;89(4):817-28. doi: 10.1016/j.mcna.2005.02.006. Med Clin North Am. 2005. PMID: 15925652 Review.
-
Sarcoidosis Epidemiology: Race Matters.Front Immunol. 2020 Sep 15;11:537382. doi: 10.3389/fimmu.2020.537382. eCollection 2020. Front Immunol. 2020. PMID: 33042137 Free PMC article. Review.
Cited by
-
Feasibility, utility and symptom impact of modified mindfulness training in sarcoidosis.ERJ Open Res. 2018 May 8;4(2):00085-2017. doi: 10.1183/23120541.00085-2017. eCollection 2018 Apr. ERJ Open Res. 2018. PMID: 29750143 Free PMC article.
-
Sarcoidosis: An Ill-afforded Disease.Am J Respir Crit Care Med. 2020 Apr 15;201(8):890-891. doi: 10.1164/rccm.202001-0047ED. Am J Respir Crit Care Med. 2020. PMID: 31978312 Free PMC article. No abstract available.
-
Pulmonary sarcoidosis: differences in lung function change over time.Thorax. 2024 Oct 16;79(11):1033-1039. doi: 10.1136/thorax-2023-221309. Thorax. 2024. PMID: 38906696 Free PMC article.
-
Reproductive and hormonal risk factors for sarcoidosis: a nested case-control study.BMC Pulm Med. 2022 Jan 24;22(1):43. doi: 10.1186/s12890-022-01834-1. BMC Pulm Med. 2022. PMID: 35073900 Free PMC article.
-
Morbidity and mortality in sarcoidosis.Curr Opin Pulm Med. 2014 Sep;20(5):472-8. doi: 10.1097/MCP.0000000000000080. Curr Opin Pulm Med. 2014. PMID: 25029298 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical